In this randomized , multicenter , double-blind , placebo-controlled , phase III trial , adults with RA were randomly assigned to receive IV placebo ( n = 197 ) or golimumab 2 mg/kg ( n = 395 ) infusions at Week 0 , Week 4 , and every 8 weeks thereafter .